Biograil has raised EUR 3 million from High-Tech Gründerfonds, Megatrend Invest and investiere

Biograil was established in 2019 and is a spin-off from Egalet/Zyla Life Sciences. Biograil is a pre-clinical stage pharmaceutical company leveraging its proprietary BIONDD technology to unlock the potential of transforming markets of injectable pharmaceutical products into convenient oral capsules.

Biograil is developing a pill that delivers macromolecular medications via the oral route instead of injections. It is based on a patent-pending hooking design made of biodegradable polymers that are able to attach to the intestinal wall. Animal tests have shown that this mechanism is at least as effective as subcutaneous injections.

“Biograil’s technology platform could become a game-changer that offers convenience for patients and a large commercial opportunity for pharma companies in many indications”, explains Susanne Schorsch, Investment Manager for investiere.

Offering an oral route instead of injections would be a major breakthrough, which is why big companies such as Novartis or Alphabet are investing heavily in concepts such as robotic pills. Faced with such competition, CEO and founder of Biograil, says: “Our strongest asset is simplicity.” (Read our interview with Karsten.)

The company has established the partnerships necessary to go forward with pre-clinical trials (designing, manufacturing and testing the device). Afterward, pharma companies could go into clinical trials based on license agreements.

Biograil will use the funds to optimize the design of its delivery device and for preclinical testing.